Combined vaginal progesterone and cervical cerclage in the prevention of preterm birth: a systematic review and meta-analysis.


Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
08 2023
Historique:
received: 28 02 2023
revised: 15 05 2023
accepted: 15 05 2023
medline: 7 8 2023
pubmed: 22 5 2023
entrez: 21 5 2023
Statut: ppublish

Résumé

Vaginal progesterone and cervical cerclage are both effective interventions for reducing preterm birth. It is currently unclear whether combined therapy offers superior effectiveness than single therapy. This study aimed to determine the efficacy of combining cervical cerclage and vaginal progesterone in the prevention of preterm birth. We searched Medline (Ovid), EMBASE (Ovid), PsycINFO (Ovid), CINAHL (EBSCOhost), Cochrane Library (Wiley), and Scopus (from their inception to 2020). The review accepted randomized and pseudorandomized control trials, nonrandomized experimental control trials, and cohort studies. High risk patients (shortened cervical length <25mm or previous preterm birth) who were assigned cervical cerclage, vaginal progesterone, or both for the prevention of preterm birth were included. Only singleton pregnancies were assessed. The primary outcome was birth <37 weeks. Secondary outcomes included birth <28 weeks, <32 weeks and <34 weeks, gestational age at delivery, days between intervention and delivery, preterm premature rupture of membranes, cesarean delivery, neonatal mortality, neonatal intensive care unit admission, intubation, and birthweight. Following title and full-text screening, 11 studies were included in the final analysis. Risk of bias was assessed using the Cochrane Collaboration tool for assessing the risk of bias (ROBINS-I and RoB-2). Quality of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) tool. Combined therapy was associated with lower risk of preterm birth at <37 weeks than cerclage alone (risk ratio, 0.51; 95% confidence interval, 0.37-0.79) or progesterone alone (risk ratio, 0.75; 95% confidence interval, 0.58-0.96). Compared with cerclage only, combined therapy was associated with preterm birth at <34 weeks, <32 weeks, or <28 weeks, decreased neonatal mortality, increased birthweight, increased gestational age, and a longer interval between intervention and delivery. Compared with progesterone alone, combined therapy was associated with preterm birth at <32 weeks, <28 weeks, decreased neonatal mortality, increased birthweight, and increased gestational age. There were no differences in any other secondary outcomes. Combined treatment of cervical cerclage and vaginal progesterone could potentially result in a greater reduction in preterm birth than in single therapy. Further, well-conducted and adequately powered randomized controlled trials are needed to assess these promising findings.

Identifiants

pubmed: 37211087
pii: S2589-9333(23)00166-0
doi: 10.1016/j.ajogmf.2023.101024
pii:
doi:

Substances chimiques

Progesterone 4G7DS2Q64Y

Types de publication

Meta-Analysis Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101024

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Anne-Marie Aubin (AM)

John Hunter Hospital, New Lambton Heights, New South Wales, Australia (Drs Aubin, L. McAuliffe, and Sabdia).

Liam McAuliffe (L)

John Hunter Hospital, New Lambton Heights, New South Wales, Australia (Drs Aubin, L. McAuliffe, and Sabdia).

Kimberley Williams (K)

Western Australian Country Health Service, Western Australia, Australia (Dr Williams).

Ashad Issah (A)

Northern Adelaide Local Health Network, South Australia, Australia (Dr Issah).

Rosanna Diacci (R)

Central Coast Health District, New South Wales, Australia (Dr Diacci).

Jack E McAuliffe (JE)

University of Adelaide, South Australia, Australia (Mr J. McAuliffe).

Salma Sabdia (S)

John Hunter Hospital, New Lambton Heights, New South Wales, Australia (Drs Aubin, L. McAuliffe, and Sabdia).

Jason Phung (J)

School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, New South Wales, Australia (Dr Phung, Ms Wang, and Professor Pennell); Mothers and Babies Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia (Dr Phung, Ms Wang, and Dr Pennell); Maternity and Gynaecology John Hunter Hospital, New Lambton Heights, New South Wales, Australia (Drs Phung and Pennell).

Carol A Wang (CA)

School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, New South Wales, Australia (Dr Phung, Ms Wang, and Professor Pennell); Mothers and Babies Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia (Dr Phung, Ms Wang, and Dr Pennell).

Craig E Pennell (CE)

School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Callaghan, New South Wales, Australia (Dr Phung, Ms Wang, and Professor Pennell); Mothers and Babies Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia (Dr Phung, Ms Wang, and Dr Pennell); Maternity and Gynaecology John Hunter Hospital, New Lambton Heights, New South Wales, Australia (Drs Phung and Pennell). Electronic address: Craig.Pennell@newcastle.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH